Recent meta-analysis reveals that alpha-methylacyl-CoA racemase (AMACR) has a sensitivity of 90 percent and specificity of 91 percent for diagnosing prostate cancer via immunohistochemistry (IHC) in biopsy samples. The study included 37 reports with nearly 5,900 samples and noted a slight reduction in performance for reverse transcription-polymerase chain reaction (RT-PCR) methods, particularly in urine and serum analyses. Geographic variance in sensitivity was observed, highlighting the need for standardization in diagnostic practices.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
